Schroder Investment Management Group’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.3M | Buy |
72,875
+47,798
| +191% | +$10.5M | 0.01% | 570 |
|
|
2026
Q1 | $4.74M | Sell |
25,077
-15,290
| -38% | -$2.67M | ﹤0.01% | 791 |
|
|
2025
Q4 | $6.9M | Buy |
+40,367
| New | +$6.19M | 0.01% | 704 |
|
|
2025
Q3 | – | Sell |
-17,816
| Closed | -$1.89M | – | 1224 |
|
|
2025
Q2 | $1.89M | Buy |
17,816
+8,444
| +90% | +$917K | ﹤0.01% | 918 |
|
|
2025
Q1 | $1.15M | Buy |
+9,372
| New | +$1.22M | ﹤0.01% | 973 |
|
|
2024
Q4 | – | Sell |
-50,555
| Closed | -$5.61M | – | 1222 |
|
|
2024
Q3 | $5.61M | Buy |
50,555
+19,412
| +62% | +$2.13M | 0.01% | 767 |
|
|
2024
Q2 | $3.32M | Sell |
31,143
-27,114
| -47% | -$2.98M | ﹤0.01% | 858 |
|
|
2024
Q1 | $7.02M | Buy |
58,257
+10,698
| +22% | +$1.31M | 0.01% | 722 |
|
|
2023
Q4 | $5.85M | Buy |
47,559
+43,044
| +953% | +$5.37M | 0.01% | 735 |
|
|
2023
Q3 | $584K | Sell |
4,515
-3,792
| -46% | -$505K | ﹤0.01% | 1072 |
|
|
2023
Q2 | $1.03M | Sell |
8,307
-116,318
| -93% | -$15.7M | ﹤0.01% | 1048 |
|
|
2023
Q1 | $18.2M | Sell |
124,625
-24,995
| -17% | -$3.7M | 0.03% | 494 |
|
|
2022
Q4 | $23.8M | Buy |
149,620
+13,596
| +10% | +$1.99M | 0.04% | 417 |
|
|
2022
Q3 | $18.1M | Sell |
136,024
-6,242
| -4% | -$949K | 0.03% | 466 |
|
|
2022
Q2 | $22.2M | Sell |
142,266
-42,941
| -23% | -$6.61M | 0.03% | 437 |
|
|
2022
Q1 | $29.2M | Buy |
185,207
+38,921
| +27% | +$5.65M | 0.04% | 405 |
|
|
2021
Q4 | $18.6M | Sell |
146,286
-22,105
| -13% | -$2.91M | 0.02% | 480 |
|
|
2021
Q3 | $21.9M | Buy |
168,391
+33,752
| +25% | +$5.1M | 0.03% | 465 |
|
|
2021
Q2 | $23.9M | Buy |
134,639
+23,557
| +21% | +$4.08M | 0.03% | 477 |
|
|
2021
Q1 | $18.3M | Buy |
111,082
+21,223
| +24% | +$3.49M | 0.02% | 529 |
|
|
2020
Q4 | $14.8M | Sell |
89,859
-14,850
| -14% | -$2.21M | 0.02% | 554 |
|
|
2020
Q3 | $15M | Sell |
104,709
-26,289
| -20% | -$3.26M | 0.02% | 494 |
|
|
2020
Q2 | $14.5M | Buy |
130,998
+2,047
| +2% | +$226K | 0.03% | 486 |
|
|
2020
Q1 | $13.6M | Sell |
128,951
-61,548
| -32% | -$7.96M | 0.03% | 458 |
|
|
2019
Q4 | $28.4M | Buy |
190,499
+24,131
| +15% | +$3.28M | 0.05% | 415 |
|
|
2019
Q3 | $21.2M | Sell |
166,368
-109,432
| -40% | -$14.7M | 0.04% | 445 |
|
|
2019
Q2 | $39.3M | Buy |
275,800
+247,947
| +890% | +$33.3M | 0.03% | 466 |
|
|
2019
Q1 | $3.98M | Hold |
27,853
| – | – | 0.01% | 729 |
|
|
2018
Q4 | $3.45M | Sell |
27,853
-750
| -3% | -$111K | 0.01% | 729 |
|
|
2018
Q3 | $4.81M | Sell |
28,603
-115,950
| -80% | -$19.9M | 0.01% | 707 |
|
|
2018
Q2 | $25.1M | Sell |
144,553
-76,747
| -35% | -$12.5M | 0.04% | 409 |
|
|
2018
Q1 | $33.4M | Sell |
221,300
-32,600
| -13% | -$4.78M | 0.06% | 348 |
|
|
2017
Q4 | $34.2M | Sell |
253,900
-101,000
| -28% | -$14M | 0.06% | 367 |
|
|
2017
Q3 | $52.6M | Buy |
+354,900
| New | +$53.7M | 0.09% | 275 |
|
|
2014
Q2 | – | Sell |
-16,100
| Closed | -$2.23M | – | 1413 |
|
|
2014
Q1 | $2.23M | Sell |
16,100
-22,900
| -59% | -$3.45M | ﹤0.01% | 890 |
|
|
2013
Q4 | $4.94M | Buy |
39,000
+5,400
| +16% | +$559K | 0.01% | 800 |
|
|
2013
Q3 | $3.09M | Buy |
33,600
+9,400
| +39% | +$758K | 0.01% | 836 |
|
|
2013
Q2 | $1.66M | Buy |
+24,200
| New | +$1.48M | ﹤0.01% | 926 |
|
Other funds holding JAZZ
Schroder Investment Management Group's JAZZ Position: Q2 2026 in Review
Schroder Investment Management Group increased its Jazz Pharmaceuticals (JAZZ) stake by 191% in Q2 2026, buying an estimated $10.5M and bringing the position to 72,875 shares worth $17.3M. The position accounts for 0.01% of the portfolio, ranked #570.
Schroder Investment Management Group first reported a position in JAZZ in Q2 2013 and has held it in 38 quarters since. The position peaked at $52.6M in Q3 2017. 646 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.
- Schroder Investment Management Group held 72,875 shares of Jazz Pharmaceuticals worth $17.3M as of Q2 2026.
- Schroder Investment Management Group bought 47,798 Jazz Pharmaceuticals shares in Q2 2026, an estimated $10.5M.
- Jazz Pharmaceuticals made up 0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #570 holding.
- Schroder Investment Management Group first reported a position in Jazz Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
- Schroder Investment Management Group's Jazz Pharmaceuticals position peaked at $52.6M in Q3 2017.
- 646 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.
Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.